With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles
are evolving. There is an urgent and unmet need of approaches to optimally manage …

Cognitive impairment is a debilitating side effect experienced by patients with cancer treated
with systemically administered anticancer therapies. With around 19.3 million new cases of …

Chimeric antigen receptor T-cell therapy and bispecific T-cell recruiting antibodies have
transformed the treatment landscape for relapsed/refractory multiple myeloma, with B-cell …

While cytokine release syndrome and immune effector cell‐associated neurotoxicity
syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell …

Chimeric antigen receptor (CAR) T-cell therapy can lead to durable responses in patients
with relapsed/refractory hematologic malignancies. Immune effector cell–associated …

Background This systematic review aimed to characterise the cognitive outcomes of patients
who received chimeric antigen receptor T-cell therapy. Methods A systematic search of the …

Cancer treatment is associated with long lasting cognitive impairment in cancer survivors.
This cognitive impairment is often termed cancer related cognitive impairment (CRCI) …

Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought
substantial improvement in clinical outcomes in patients with relapsed/refractory B cell …

The tremendous successes of CD19-directed CAR T cells in children and young adults with
B-cell acute lymphoblastic leukemia (B-ALL) has led to the more widespread use of this …

Chimeric antigen receptor T-cell (CAR T-cell) therapies have emerged as a promising
treatment modality for several malignancies, particularly haematological malignancies, by …